BD2Decide

Big Data and models for personalized Head and Neck Cancer Decision support

TITLE	Dissemination materials – first release		
Deliverable No.	D9.5		
EDITOR	MME – F. Mercalli, S. Copelli		
Contributors	ATC		
WorkPackage No.	WP9	**WorkPackage Title**	Communication & Exploitation
Status[1]	Final	**Version No.**	1.0
Delivery date	31/08/2016	**Actual delivery date**	31/08/2016
Dissemination level	PU		
DOCUMENT ID	D9.5 Dissemination materials – first release		
FILE ID	BD2Decide D9.5		
Related documents	Technical Annex I DoA version 21/10/2015		

---

[1] Status values: TOC, DRAFT, FINAL

Distribution List

Organization	Name of recipients
AOP	T. Poli, E.M. Silini, S. Rossi, E. Martinelli, G. Chiari, C. Caminiti, G. Maglietta
VUMC	R. H. Brakenhoff, H. Berkhof, P. va de Ven
UDUS	K. Scheckenbach
INT	F. Favales, L. Licitra, G. Calareso, G. Gatta, A. Trama
UPM	G. Fico
Fraunhofer	F. Jung, S. Wesarg
ATC	V. Tountopoulos
AII	A. Algom
POLIMI	L. Mainardi, V.Corino, E. Montin
MAASTRO	P. Lambin, F. Hoebers
MME	S. Copelli, F. Mercalli
UNIPR	S. Rossi
European Commission	Project Officer: and all concerned E.C. appointed personnel and external experts

This document should be distributed as guidance to all the personnel of BD2Decide Consortium partners involved in the project execution.

Revision History

Revision no.	Date of Issue	Author(s)	Brief Description of Change
0	01.07.2016	F. Mercalli, S. Copelli (MME)	ToC
1	31.08.2016	F. Mercalli, S. Copelli (MME)	Finalized version

Addressees of this document

This document presents the diverse materials that are intended to support the Project communication plan and strategy, as presented in Deliverable 9.2.

The deliverable will be revised twice (second release at M20 and third release at M32), in order to take into account additional insights, obtained during the course of project.

This document will be delivered to the European Commission.

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF TABLES

Abbreviations and definitions

CA	Consortium Agreement
DoA	Description of Action, Technical Annex I to the Grant Agreement
EC	European Commission
EU	European Union
GA	Grant Agreement

Executive summary

This document – the first one of a total of three releases – presents the dissemination materials implemented to date, aimed at supporting the Project's communication and dissemination strategy, as established in deliverable D9.2 [4].

In particular it describes in details the Project's logo, slide presentations template, social network accounts, leaflet, newsletter format and editorial plan, and the overall structure of a video presentation to be implemented by the second release of this document.

The implemented materials are all available online and/or in electronic form. It will be up to the Consortium to decide if some of them (e.g. leaflet, newsletter) will need to be transposed on paper, according to the different dissemination opportunities that will be identified during the course of the Project.

1   RATIONALE FOR THE DISSEMINATION MATERIALS

The BD2Decide communication strategy, illustrated in deliverable D9.2 [4] needs to be supported by relevant dissemination materials, in order to reinforce and substantiate the messages that the Project will publish externally.

This deliverable, which is to be issued in three releases (the second one is D9.6, due at M20, and the third one is D9.7, due at M32), presents the first set of such materials, as it has been elaborated to date.

In particular, it comprises the following elements:

- Project Logo

- Project presentations template

- Project social network accounts

- Project leaflet

- Project newsletter format and editorial plan
- Project video presentation

The following sections illustrate each of these elements in detail.

2   PROJECT LOGO

Created by designers at ATC, the Project Logo – represented in Figure 1 – boldly projects the acronym of the action, through an assertive two-colors palette, reminiscent of the medical environment.

An outlined DNA segment, leaning on the first letter of the acronym, represents the "big data" foundation of the Project.

The logo is made available for all Project's Communication activities in the following formats:

- Low resolution 285 pixel x 59 pixel, PNG format

- Low resolution 285 pixel x 59 pixel, PNG format with transparent background

- High resolution 1179 pixel x 237 pixel, EPS format

- High resolution 1179 pixel x 237 pixel, JPG format

- High resolution 1179 pixel x 237 pixel, PNG format with transparent background

Figure 1. BD2Decide Logo

The DNA segment outline is also employed as a 16 pixel x 16 pixel "favicon" for usage on webpages, as represented in Figure 2.


Figure 2. BD2Decide favicon (enlarged)

3 SLIDE PRESENTATIONS TEMPLATE

Based on the Project Logo, a slide presentation template has also been prepared.

This template shall be used for both:

- Presentations internal to the Consortium (e.g. during Consortium plenary meetings or Technical meetings)

- All presentation external to the Consortium (e.g. presentations at conferences, workshops, meetings with prospective users or customers, etc.)

This will help in promoting the consistency and uniformity of BD2Decide's communication actions and in reinforcing brand recognition.

In particular, the template proposes three different page "masters":

- Cover slide (see Figure 3): it includes the Project Logo, the presentation title, the name of the presenter and its function/organization, and the date/venue of the presentation

- Main content slides (see Figure 4): free hand is left to the presenter to decide the instance content (text, images, multimedia, etc.) in the frame of a mandatory structure, comprising a title and the bullet format for text content

- Final slide (see Figure 5): it comprises a concluding message, acknowledgment of the H2020 funding, the Project website URL and the QR Code to directly visit the website. From a communication point of view, this slide is very important for external presentations, as it reinforces:

  o the contribution from the H2020 Programme and, indirectly, the European scale of the BD2Decide endeavor

  o the invitation to obtain more information on the Project and get in contact with the Consortium, by highlighting the website entry point

The following figures visually illustrate the above described slides.

<presentation title>

Name of the presenter

Function and Organisation

Date &
Venue

Figure 3. BD2Decide presentation template: cover slide

<slide title>

☐ <main text>

Slide 2

Figure 4. BD2Decide presentation template: main slides

Figure 5. BD2Decide presentation template: final slide

4 PROJECT SOCIAL NETWORK ACCOUNTS

Social network accounts have been created in order to sustain inbound communication, as defined in D9.2 [4] Section 2.3.

In particular, the following accounts have been created:

- Twitter account at http://twitter.com/bd2decide (see Figure 6): it is intended as a "lean" channel, suitable to inform all target groups about what is going on in general in BD2Decide. Published micro-posts will possibly contain a link to more in-depth content, issued on other channels (such as the Project Blog) for interested readers.

- Facebook page at http://facebook.com/bd2decide (see Figure 7): given its wide appeal on a large number of users and the possibility to add images and videos that convey more intensive and expressive messages, this channel is mainly intended to reach the General Public as well as Patients Associations and Cancer Research NGOs.

Management credentials for the accounts have been assigned to the following Partners, in order to allow them to conduct related workflow activities, as illustrated in D9.2 [4] Section 2:

- MME, as Work-package Leader of *WP9 Communication & Exploitation* to ensure the overall coordination of the social network communication

- AOP, as Project Coordinator, to supervise the communication messages and guarantee their adherence to the BD2Decide objectives

- ATC, as webmaster of the BD2Decide Website, in order to ensure appropriate technical linkages across social network publishing and web publishing (e.g. automatic Twitter notification of new posts in the Project Blog)

Figure 6. BD2Decide Twitter account (twitter/bd2decide)

Figure 7. BD2Decide Facebook page (facebook.com/bd2decide)

At the moment, no LinkedIn dedicated Group has been created yet. In fact, this is a decision to be made in subsequent releases of this deliverables, as the creation of a specific LinkedIn Group, able to attract wide professional interest, requires the continuous provision of high quality, in-depth content – an activity that may be beyond the main objectives of the Project. Moreover, the opening of a new LinkedIn Group is justified only if the lack of relevant information/discussions from other, already accessible Groups is ascertained.

As mentioned in D9.2 [4] Section 2.3, the current Consortium strategy with LinkedIn is to participate in existing Groups focused on scientific, technical and business areas of interest to the Project.

At the time of writing, the participation of BD2Decide team members has been accepted in the LinkedIn Groups listed in

Population Health Management, Accountable Care Organizations, Healthcare Data Analytics PHM ACO BIG https://www.linkedin.com/groups/1802791	This group is focused on the next wave of healthcare IT implementations. 73% of all hospitals report population health management as the next big implementation plan. It will discuss PHM issues, Accountable Care Organizations (ACO's) and /or large healthcare systems, and how they feed into PHM. It will address the needs, and requirements of the big data created by EMR's (EHR), and how to deliver smart healthcare data analytics.	BD2Decide will illustrate how the application of CDSSs and big data analytics can impact care management and provide tangible advantages to healthcare authorities and care organizations. The Visualization Suite, including the patient co-decision tool, is also a topic of potential interest for this Group.
CT & MRI Medical Imaging https://www.linkedin.com/groups/142087	The CT & MRI Medical Imaging group is one of the largest clinical groups providing peer reviewed / moderated content & contributions. We guard against spam and trolls to provide a CLINICAL focus toward CT, MR, PET/CT, & PET/MR.	BD2Decide conversations in this Group will focus on the application of new imaging techniques and radiomics methods to improve HNC prediction in prognostic models and CDSSs.

Table 1.

In particular, the table reports:

- Group identification (icon, name and URL)

- Group description (as provided by the Group managers)

- Motivation for participation in the Group, with reference to the three main markets targeted by BD2Decide (as listed in DoA, Part B, Section 2.2.1 Exploitation planning): Clinical Decision Support Systems, Medical Imaging, Big Data Analytics

Group ID	Description	Motivation
Big Data and Analytics https://www.linkedin.com/groups/4332669	A network for individuals interested in Big Data with collated industry news and exclusive opinions, features & events.	BD2Decide can attract interest on the usage of Big Data Analytics for cancer treatment.
Healthcare-IT/ EHR/ HIS https://www.linkedin.com/groups/37886	This group is for people working in Healthcare, Pharma, Lifesciences, Health Insurance, Medical Devices, eHealth, mHealth, EHR, Hospital Info System (HIS), PRM, HC SMAC, HC IoT. Knowledge grows by sharing.	BD2Decide will contribute to the Group its vision on the creation and application of CDSSs for cancer treatment, based on prognostic modelling and data analytics.

Group ID	Description	Motivation
Data Science in Healthcare https://www.linkedin.com/groups/7010492	Data science, machine learning, data mining, information retrieval, natural language processing, predictive modeling, statistics, text mining, image processing, big data, visualization, business analytics, business intelligence – as applied towards the quadruple aim of healthcare. Science, technology and applications are all welcome, including clinical decision support, population health analytics, patient risk prediction, patient safety, precision medicine, personalized medicine, clinical analytics, medical informatics, translational medicine, patient monitoring, epidemiology and biostatistics. Please contribute to an open, vendor neutral and evidence based discussion – so that we can all learn from each other, build stronger relationships and help healthcare improve faster.	This Group is central to the BD2Decide view on HNC treatment. Conversations can touch many Project pillars, such as: • Usage of big data analytics in prognostic modelling and HNC decision support • Usage of advanced medical imaging and radiomics in prognostic modelling and HNC CDSSs • Role of data visualisation suites • Role of patient co-decision tools and personalized patient treatment strategies • Etc.
Population Health Management, Accountable Care Organizations, Healthcare Data Analytics PHM ACO BIG https://www.linkedin.com/groups/1802791	This group is focused on the next wave of healthcare IT implementations. 73% of all hospitals report population health management as the next big implementation plan. It will discuss PHM issues, Accountable Care Organizations (ACO's) and /or large healthcare systems, and how they feed into PHM. It will address the needs, and requirements of the big data created by EMR's (EHR), and how to deliver smart healthcare data analytics.	BD2Decide will illustrate how the application of CDSSs and big data analytics can impact care management and provide tangible advantages to healthcare authorities and care organizations. The Visualization Suite, including the patient co-decision tool, is also a topic of potential interest for this Group.

Group ID	Description	Motivation
CT & MRI Medical Imaging https://www.linkedin.com/groups/142087	The CT & MRI Medical Imaging group is one of the largest clinical groups providing peer reviewed / moderated content & contributions. We guard against spam and trolls to provide a CLINICAL focus toward CT, MR, PET/CT, & PET/MR.	BD2Decide conversations in this Group will focus on the application of new imaging techniques and radiomics methods to improve HNC prediction in prognostic models and CDSSs.

Table 1. LinkedIn Groups in which BD2Decide team members are participating

5 PROJECT LEAFLET

The objective of the Project Leaflet is to support communication through outbound channels, such as press releases, workshops, etc. (see D9.2 [4] Section 2.3)

It contains relevant, general information on the Project and its main objectives, in order to provide a quick and clear overview of the overall BD2Decide endeavor.

Being directed toward most of the actors' categories targeted by the Project (D9.2 [4], Section 1.1), the Project Leaflet tries to strike a balance among the diverse information needs of these actors and acts as a kind of "hub" referring to additional, more specific Project channels.

The main criteria that underpin the leaflet design are the following:

- Build on the Logo look & feel, in order to bring uniformity and increase brand recognition.

- Provide a quick overview of the Project rationale

- Provide a drilldown into the five major Project Objectives (as reported in DoA, Part B, Section 1.1)

- Provide the list of Consortium Partners and as well as a specific contact person (from the Coordinator)

- Clearly indicate additional Project Communication channels, where readers can find more information

The Leaflet is laid out as a classical A4 format, tri-fold business brochure, with a total of 6 pages.

In the cover page, the BD2Decide logo is prominently shown, together with the acronym and the full title of the Action.

In the last page, which is easily accessible even when the Leaflet is folded up, a brief yet clear Project summary is proposed, for readers to get immediately acquainted with what BD2Decide stands for. In this page, information on EU funding – with the claim mandated by DoA (article 27.3) and the EU emblem – is also included in a prominent position.

The list of Consortium Partners is reported in the last external page, in a way that suggests its EU-wide scale. This page also reports the Coordinator's contact point, with his name and email address.

In the three internal pages the five major Project Objectives are illustrated, in the following order:

- O1. Big Data Techniques

- O2. Prognostic Models

- O3. Imaging and Radiomics

- O4. Visualization Suite

- O5. Clinical validation

In the last of these pages, after the description of the objectives, an invitation to visit the Project's online communication channels – namely the Project website, the Project Twitter account and the Project Facebook page – is included.

In order to encourage readers to accept this invitation, the following elements have been added:

- Clear invitation text, proposing to get more information and asking for comments and opinions from readers

- A graphic element, with a representation of one of the BD2Decide social network channels, to attract the eye

- Three QR codes, one on each internal page, directly linking the reader to the Project's online channels (the Project website, the Project Twitter account and the Project Facebook page, as above mentioned)

In the following Figure 8 and Figure 9, the general appearance of the Leaflet is presented.

THE PARTNERSHIP

BD2Decide is conducted by an international partnership that includes 4 research institutions, 5 cancer clinics and 3 ICT companies.

Italy
- Azienda Ospedaliero Universitaria di Parma
- MultiMed Engineers srls
- Fondazione IRCCS Istituto Nazionale dei Tumori
- Politecnico di Milano
- Università degli Studi di Parma

Germany
- Heinrich-Heine-Universität Düsseldorf
- Fraunhofer IGD Visual Computing

Greece
- Athens Technology Center S.A.

Israel
- All in Image Ltd

Netherlands
- Stichting VU University Medical Center
- MAASTRO

Spain
- Universidad Politecnica de Madrid

CONTACT
Dr. Tito Poli
Azienda Ospedaliero Universitaria di Parma (Italy)
Email: BD2Dcoord@ao.pr.it

WHAT IS BD2DECIDE?

BD2Decide builds on the joint deployment of (i) data management techniques for "big data" and (ii) an integrated library of analytical models validated by the scientific community, to improve the prognosis and treatment of head and neck cancer.

Cancers of the head and neck region are the 6th more deadly cancers worldwide (in Europe around 150,000 new cases are detected each year) and their treatment can have hard impact on patient's aesthetics and essential functionalities, contributing to a substantial decrease in quality of life.

The intrinsic heterogeneity of such tumours makes their understanding particularly difficult and in most cases the diagnosis is made at later stages, when therapeutic impact is heavier and results are less certain.

The increased availability of new data –both in quality and quantity– is challenging the world of ICT technologies to obtain much more precise prognostic predictions, to implement first-line treatments which maximize therapeutic results and minimize the impacts on the patients' quality of life.

BD2Decide is a cloud based, distributed infrastructure, that will be available to healthcare centres across Europe.

BIG DATA AND MODELS FOR PERSONALIZED HEAD AND NECK CANCER DECISION SUPPORT

Figure 8. Project Leaflet: external pages

BIG DATA TECHNIQUES

BD2Decide deploys Big Data techniques to discover and validate personalized, based prognostic patterns that outperform current practice. This objective is being achieved through:

- The setup of an appropriate cloud computing infrastructure to collect and homogenize data, in compliance to state-of-art standards.
- The application of data analytics to categorize each individual patient and each cancer sub-type, to find person-specific patterns and to apply the most suited prognostic models.

PROGNOSTIC MODELS

BD2Decide enriches and refines existing prognostic models, to obtain an improved and more personalised prediction, through:

- The combination of different models into a single pooled estimate (synthesis analysis)
- The updating of existing models using newly available data sets and adaptive Bayesian machine learning techniques
- The scoring of prognostic factors, to provide physicians with additional insight into the added value brought to the prognosis by each factor.

IMAGING AND RADIOMICS

BD2Decide refines and validates advanced imaging and radiomics tools, for the discovery of new prognostic signatures. In particular:

- It implements a functional imaging analysis and features extraction tool, that derives new information from images and calculate tumour and lymph-nodes volumes from CT/MRI.
- It implements a radiomics software applied to CT, MRI and DWI MRIs to capture phenotypic heterogeneity in tumours.

VISUALIZATION SUITE

BD2Decide develops a highly interactive visualization and presentation suite for tumour understanding and treatment, based on:

- Digital Patient exploration tools, for easier access to data by clinicians.
- A co-decision environment, to actively engage patients in the therapeutic process, in line with the "no decision about me without me" initiative.
- The development of an assistive data visualization and presentation suite aimed at supporting medical researchers.

VALIDATION

Clinical validation of the system is conducted in different EU populations, based on around 1000 retrospective cases and 450 prospective cases, collected in the 5 participating clinical centres.

Follow Us

Get more information, provide your comments and opinions, contact us.

Follow us on our online channels:

- Website: **www.bd2decide.eu**
- Twitter: **twitter.com/bd2decide**
- Facebook: **facebook.com/bd2decide**

Figure 9. Project Leaflet: internal pages

6   PROJECT NEWSLETTER FORMAT AND EDITORIAL PLAN

The Project newsletter represents one of the most important outbound channels for BD2Decide. The newsletter is well suited for sending through mailing lists managed by each Consortium Partner, or to other 1-to-many channels accessible to the Consortium.

In a sense, it is the main institutional herald for announcing Project advancements.

As such, the newsletter must satisfy several requirements:

- It should be issued when major steps forward have been accomplished by the Project, in order to provide an authoritative voice on what has been achieved, what are the impacts of those achievements and what will be the next moves. Ideally, a newsletter issue should be published at each Project milestone (see milestone list in DoA, Part A, Section 1.3.4)

- It should strive to address multiple categories of targeted actors – although the focus is mainly on professional actors and policy makers that need reference material, not only to be informed but also, in turn, to inform others players that could be involved in potential deployment and exploitation endeavors

- It should be, at the same time, rigorous and "to the point" but also concise and efficient to read

In order to address these requirements, the following general structure is proposed for each newsletter issue:

- **Editorial Leader**: to sum up the work done by the project since the previous newsletter issue; it should focus on measurable results obtained, advantages brought to the addressed user categories and a brief indication of plans for advancing the work. The editorial leader should be written by the Project Coordinator, possibly with the support of the Leader of *WP9 Communication & Exploitation*

- One or more **articles on specific, technical results achieved in the period**. These articles can focus on technical aspects of the results and should highlight in particular what are the innovations contributed by the Project, given the current state of the art. These articles should be written by technical Partners, leading the implementation work for the relevant technical components

- One or more **articles on usage scenarios**, either real ones – as experimented in the Project validation activities – or hypothetical ones, as they will be proposed to potential users and customer during the Project exploitation phase. These articles should be written by clinical Partners and should focus on the impact of BD2Decide in the clinical settings, discussing when possible the achievement of the Key Performance Indicators mentioned in the DoA, Part B, Section 2.1 (Expected Impacts).

- One or more **small snippets on liaison actions or events** conducted by the BD2Decide Consortium or by individual Partners toward specific actors categories (e.g. presentation to conferences or in scientific journals, organization of workshops, participation to relevant trade fairs, etc.)

- Clearly mentioned **contact coordinates**, for readers that would like to obtain more information or get in touch with the Consortium

Figure 10 and Figure 11 show the proposed graphical representation for the above structure, which is based on the Project Logo and its graphical style, as presented in Section 2 above.

The Figures illustrate the format for the first page (which includes the Editorial Leader) and last page (which includes the invitation to contact the Consortium). In addition, newsletter issues may have any additional number of middle pages, containing more articles and more snippets on liaison actions or events.

BD2DECIDE

Big Data and Models for Personalized
Head and Neck Cancer Decision Support

NEWSLETTER 01

30 November 2016
Page 1 / 2

Article Title

Subtitle

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus commodo nulla nec elit mattis tempus.

Nunc tempus, tellus at volutpat tincidunt, tellus urna placerat lorem, at bibendum augue justo lacinia enim. Praesent dictum mi blandit felis vehicula elementum.

Curabitur odio dolor, convallis quis massa at, ullamcorper blandit tortor. Aliquam dui elit, bibendum bibendum augue vel, consequat gravida elit. Suspendisse ut nulla non libero sodales tincidunt. Proin quis faucibus risus, nec congue lectus. Nam ornare, turpis ut ultricies semper, arcu diam varius nunc, et porta velit elit non ligula. Etiam consectetur ante tortor, non placerat sem congue vel.

Sed id eros at nibh fringilla blandit. Quisque cursus sodales justo a rhoncus. Etiam in orci est. Etiam quis velit libero. Mauris lobortis felis eu arcu vulputate euismod. Suspendisse pretium in justo eget auctor quis massa at, ullamcorper blandit quis massa at, ullamcor.

Suspendisse viverra tempor sapien, maximus hendrerit nibh consequat vitae. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Ut vitae sollicitudin nisl, nec dictum erat.

Etiam sit amet posuere enim, non gravida mauris. Proin sit amet mi risus. Ut at tempor sapien. Sed eu ornare nisi, in bibendum quam. Praesent ac bibendum sapien.

Nulla eget justo lacus. Sed pulvinar facilisis quam, id commodo lectus luctus in. Fusce eu felis dui

Article Title

Article subtitle

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus commodo nulla nec elit mattis tempus. Nunc tempus, tellus at volutpat tincidunt, tellus urna placerat lorem, at bibendum augue justo lacinia enim. Praesent dictum mi blandit felis vehicula elementum. Curabitur odio dolor, convallis quis massa at, ullamcorper blandit tortor. Aliquam dui elit, bibendum bibendum augue vel, consequat gravida elit. Suspendisse ut

Editorial Leader

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus commodo nulla nec elit mattis tempus.

Nunc tempus, tellus at volutpat tincidunt, tellus urna placerat lorem, at bibendum augue justo lacinia enim. Praesent dictum mi blandit felis vehicula elementum. Curabitur odio dolor, convallis quis massa at, ullamcorper blandit tortor. Aliquam dui elit, bibendum bibendum augue vel, consequat gravida elit.

Suspendisse ut nulla non libero sodales tincidunt. Proin quis faucibus risus, nec congue lectus. Nam ornare, turpis ut ultricies semper, arcu diam varius nunc, et porta velit elit non ligula.

Suspendisse ut nulla non libero sodales tincidunt. Proin quis faucibus risus, nec congue lectus.

Curabitur odio dolor, convallis quis massa at, ullamcorper blandit tortor. Aliquam dui elit, bibendum bibendum augue vel, consequat gravida elit. Suspendisse ut nulla non libero sodales tincidunt. Proin quis faucibus

www.bd2decie.eu
twitter.com/bd2decide
facebook.com/bd2decide

Figure 10. BD2Decide Newsletter format, first page

BD2DECIDE

NEWSLETTER 01

Big Data and Models for Personalized Head and Neck Cancer Decision Support

30 November 2016
Page 2 / 2

nulla non libero sodales tincidunt. Proin quis faucibus risus, nec congue lectus. Nam ornare, turpis ut ultricies semper, arcu diam varius nunc, et porta velit elit non ligula. Etiam consectetur ante tortor, non placerat sem congue vel. Sed id eros at nibh fringilla blandit. Quisque cursus sodales justo a rhoncus. Etiam in orci est. Etiam quis velit libero. Mauris lobortis felis eu arcu vulputate euismod. Suspendisse pretium in justo eget auctor.

Article Title

Article subtitle

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus commodo nulla nec elit mattis tempus. Nunc tempus, tellus at volutpat tincidunt, tellus urna placerat lorem, at bibendum augue justo lacinia enim. Praesent dictum

mi blandit felis vehicula elementum. Curabitur odio dolor, convallis quis massa at, ullamcorper blandit tortor. Aliquam dui elit, bibendum bibendum augue vel, consequat gravida elit. Suspendisse ut nulla non libero sodales tincidunt. Proin quis faucibus risus, nec congue lectus. Nam ornare, turpis ut ultricies semper, arcu diam varius nunc, et porta velit elit non ligula.

Article Title

Article subtitle

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus commodo nulla nec elit mattis tempus. Nunc tempus, tellus at volutpat tincidunt, tellus urna placerat lorem, at bibendum augue justo lacinia enim. Aliquam dui elit, bibendum bibendum augue vel, consequat gravida elit.

Suspendisse ut nulla non libero sodales tincidunt. Proin quis faucibus risus, nec congue lectus. Nam ornare, turpis ut ultricies semper, arcu diam varius nunc, et porta velit elit non ligula. Etiam consectetur ante tortor, non placerat sem congue vel. Sed id eros at nibh fringilla blandit. Quisque cursus sodales justo a rhoncus. Etiam in orci est.

Quis velit libero. Mauris lobortis felis eu arcu vulputate euismod. Suspendisse pretium in justo eget auctor.

Etiam consectetur ante tortor, non placerat sem congue vel. Sed id eros at nibh fringilla blandit. Quisque cursus sodales justo a rhoncus. Etiam in orci est. Etiam quis velit libero. Mauris lobortis felis eu arcu vulputate euismod. Suspendisse pretium in justo eget auctor.

Liaison action/event

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus commodo nulla nec elit mattis tempus.

Aliquam dui elit, bibendum bibendum augue vel, consequat gravida elit.

Liason action/event

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vivamus commodo nulla nec elit mattis tempus.

Aliquam dui elit, bibendum bibendum augue vel, consequat gravida elit.

You are welcome to contact us:

Dr. Tito Poli
(Project coordinator)
Azienda Ospedaliero Universitaria di Parma (Italy)
Email: BD2Dcoord@ao.pr.it

Provide your comments and opinions on our online channels indicated below or use the **QR Code** to immediately visit our website.

www.bd2decie.eu
twitter.com/bd2decide
facebook.com/bd2decide

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 689715

Figure 11. BD2Decide Newsletter format, last page

Based on this structure, the editorial plan for the BD2Decide newsletter is presented in Table 2.

In particular, for each proposed issue, the table presents:

- Dates for preparation (planning)

- Date of delivery

- Overall message (which will form the basis for the editorial leader)

- Aspects that could be addressed in the technical articles and usage scenario articles

As illustrated in the table, the precise definition of the articles titles and content will be planned within two month before the delivery date, in order to make a decision based on the actual advancements of the Project and available material.

Planning date	Delivery date (Milestone)	Overall message	Technical/applicative aspects
M10	M12 (MS2)	BD2Decide's clinical, functional and technical framework are in place. This gives to interested readers a clear understanding of what the Project is set to achieve, during the next three years.	Illustrate clinical protocols. Illustrate technical specifications.
M16	M18 (MS3)	The Project has produced its first prototypes, that provide insights into the technical and clinical challenges that are being tackled and offer an opportunity to preliminarly assess potential application scenarios.	Illustrate existing prototypes. Describe how these prototypes can be used in the clinical practice, and with what impact.
M22	M24 (MS4)	The Project has assessed and described its market requirements: the reader can learn which actors will be targeted, and how their needs are actually addressed by BD2Decide.	Discuss several clinical applications of the BD2Decide platform, based on the identified market requirements. Address how BD2Decide technical components can be proposed to different user communities (bundling, business modeling, etc.).

Planning date	Delivery date (Milestone)	Overall message	Technical/applicative aspects
M28	M30 (MS5)	The first complete version of the BD2Decide platform has been released.	Describe one or two usage scenarios that completely cover all BD2Decide functionalities. Describe how the BD2Decide technical platform can be configured and deployed at users premises and/or in the cloud.
M34	M36 (MS6)	The final version of the BD2Decide platform has been released: interested readers can start contacting the Consortium to obtain access to it.	Same as the previous issues, but with a stronger emphasis on the possibility to tailor usage and deployment scenarios to the specific needs of potential users/customers.
M38	M40 (MS7)	Final issue: farewell and invitation to contact the Consortium to procure the BD2Decide platform.	Same as previous issue, but focusing more on applicative issues (e.g. regulatory issues, from the clinical point of view, hosting and performance issues from the technical point of view, etc.)

Table 2. Newsletter editorial plan

7   PROJECT VIDEO PRESENTATION

The BD2Decide Consortium intends to prepare a video presentation of the Project, that should be used to give an immediate and "time efficient" overview of the objectives, the challenges that need to be faced and the expected results/impacts.

An important decision to be made is when to create the video, balancing two competing needs:

1. The need to have the video available as soon as possible, in order to reinforce the Project communication actions on online channels

2. The need to have enough Project results available, in order to be able to represent at best the challenges which are being faced

The best strategy to address these needs is the following:

- Wait for milestone MS2 (on M12) in order to design the detailed content of the first version of the video. In fact, at MS2, both the clinical framework and the functional/technical framework of the Project will be in place. This allows the Consortium to include content that effectively illustrates not only the Project objectives but also the specific solutions that have been chosen, from both a medical and engineering point of view.

- Wait for milestone MS3 (First prototypes available) in order to create an additional video segment – to be inserted into the first version – which, in addition to what already presented, also demonstrates the functioning of the first BD2Decide prototypes, so as to better characterize the expected configuration and impact of the Project

- The final version of the video (comprising both above mentioned parts) will be included in the second version of this deliverable (D9.6, due by M20).

In Table 3 the overall structure proposed for the video is presented.

The structure is formulated in order to illustrate all important aspects of the Project, while at the same time keep the duration under the 2:30 minutes mark, which is considered as the maximum attention span that can be required from viewers for this kind of presentation.

Release	Section	Duration	Content
1.0	Project logo, acronym and title	5 s	Brand presentation
1.0	Illustration of the needs	20 s	Explain what are the HNC clinical needs that drive the BD2Decide endeavor (e.g. reduce costs, improve prognosis, treatment, improve QoL, etc.)

Release	Section	Duration	Content
1.0	Project objectives	25 s	Illustrate the specific BD2Decide objectives, in particular: deployment of big data, prognostic modelling, usage of imaging/radiomics techniques, visualization suite and patient co-decision tool, clinical validation.
1.0	Methodology	30 s	Illustrate the clinical and technical methodologies that the project is applying in order to achieve its objectives (e.g. illustration of major components, as described in specification deliverables).
1.0	Expected impacts	20 s	Illustrate how the implementation of the BD2Decide will impact the treatment of HNC, from the points of view of: • Clinicians • Healthcare managers • Patients
2.0 (additional part to be inserted at this point)	Prototypes	30 s	Illustration of prototypes and demonstration of how they help to achieve the expect impacts
1.0	Contact info	10 s	Logos or names of Partners and contact information.
1.0	Acknowledgment of H2020 funding	10 s	EU emblem and mention "This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 689715"

Table 3. BD2Decide video structure

REFERENCES

[1] GRANT AGREEMENT NUMBER — 689715 — BD2Decide digitally sealed by the European Commission on October 21st 2015

[2] Consortium Agreement for the BD2Decide project (based on the Desca model, 2015), Version CA. Version 2016-03-03

[3] Communicating EU research and innovation guidance for project participants, version 1.0, 25 September 2014

[4] Deliverable D9.2 Communication plan and strategy, July 1st 2016, The BD2Decide Consortium